STOCK TITAN

Enlivex Therapeutics Ltd. Ordinary Shares - ENLV STOCK NEWS

Welcome to our dedicated page for Enlivex Therapeutics Ltd. Ordinary Shares news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex Therapeutics Ltd. Ordinary Shares stock.

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) is an Israel-based clinical-stage immunotherapy company focused on developing innovative allogeneic drugs to rebalance the immune system. The company's flagship product candidate, Allocetra™, is under development for multiple severe and critical conditions.

Allocetra™ is currently in a Phase IIB clinical trial targeting patients with severe sepsis, a life-threatening condition caused by the body's response to infection. Additionally, it is being investigated in a Phase II clinical trial for the treatment of COVID-19 patients with severe and critical conditions. The company is also exploring Allocetra™ in a Phase IIA trial for the prevention of graft versus host disease (GVHD) in patients undergoing allogeneic hematopoietic stem cell transplants (HSCT).

Enlivex is advancing Allocetra™ as a potential treatment for complications associated with bone marrow transplants, acute multiple organ failure, and as a combination therapy with various anti-cancer treatments to enhance efficacy. The immunotherapy works by reprogramming macrophages to their homeostatic state, thus rebalancing the immune system.

Recently, the Israeli Ministry of Health authorized a new trial for Allocetra™ targeting osteoarthritis, a chronic inflammatory condition affecting millions worldwide. This multi-country, double-blind, placebo-controlled Phase I/II trial aims to evaluate the safety and efficacy of Allocetra™ injections in knee osteoarthritis patients.

The company has shown promising results in its Phase II study of Allocetra™ in sepsis patients, demonstrating a favorable safety profile and potential effectiveness. With approvals from the Danish Medicines Agency and other international regulators, Enlivex is extending its clinical trials across multiple countries to further evaluate Allocetra™'s broad therapeutic potential.

Rhea-AI Summary

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced a Notice of Allowance from the U.S. Patent and Trademark Office for patent application number 16/594,463 regarding its sepsis treatment, Allocetra™. This patent will extend IP protection until at least 2036, enhancing its commercial potential in a largely underserved multi-billion-dollar market. The ongoing Phase II trial of Allocetra™ aims to assess safety and efficacy, with interim results anticipated in Q1 2023 and top-line data expected in Q3 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.49%
Tags
none
-
Rhea-AI Summary

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has initiated its first Phase I/II clinical trial for Allocetra™, an innovative macrophage reprogramming therapy targeting peritoneal metastases in solid cancer patients. This trial, supported by Sheba Medical Center, aims to evaluate the safety and preliminary efficacy of Allocetra™ combined with standard chemotherapy. Peritoneal cancer has a low survival rate, making new treatments critical. The trial will assess dose escalation and monitor adverse events, with the potential to redefine treatment options for patients with limited responses to existing therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
none
-
Rhea-AI Summary

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has announced a corporate update presentation at the 2022 Jefferies Healthcare Conference on June 9, 2022, at 1:00 PM ET. The company focuses on macrophage reprogramming immunotherapy, particularly its product Allocetra™, designed to treat diseases like sepsis and solid tumors. A webcast of the presentation will be accessible for 90 days. Allocetra™ aims to restore macrophage homeostasis, addressing significant medical needs by reprogramming non-homeostatic macrophages.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.58%
Tags
conferences
Rhea-AI Summary

Enlivex Therapeutics announced the Israeli Ministry of Health's authorization to begin a Phase I/II clinical trial for Allocetra™ combined with chemotherapy in patients with peritoneal metastases from solid tumors. This trial responds to the urgent need for new treatments for this terminal condition, where current therapies offer limited survival benefits. Enlivex aims to enroll approximately 12 patients, with the primary endpoint focused on safety and adverse events. The study is set to initiate in Q3 2022, following promising preclinical data suggesting Allocetra™ could enhance cancer treatment efficacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
-
Rhea-AI Summary

Enlivex Therapeutics Ltd. has announced promising preclinical findings regarding the use of Allocetra™ in combination with anti-PD1 checkpoint inhibitors for treating ovarian cancer. Conducted in collaboration with Yale Cancer Center, the study showed a survival probability of up to 50% and an 83% increase in survival duration compared to untreated groups. This highlights Allocetra’s potential to enhance checkpoint inhibitor efficacy in difficult-to-treat cancers. The results will be presented at the ASCO Annual Meeting from June 3-7, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.14%
Tags
-
Rhea-AI Summary

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has been awarded a grant of approximately $1.2 million from the Israel Innovation Authority for its ongoing sepsis clinical trial in 2022. This brings the total non-dilutive funding from the IIA to about $7.8 million since the inception of their partnership. Enlivex is currently recruiting patients for its Phase IIb trial of AllocetraTM, aimed at treating organ dysfunction associated with sepsis. AllocetraTM is designed to reprogram macrophages, potentially addressing unmet medical needs in critical conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
Rhea-AI Summary

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) appointed Roger J. Pomerantz, M.D., as Vice Chairman of its Board of Directors. Dr. Pomerantz is a seasoned pharmaceutical expert with a history of leading significant business developments, including over 150 transactions at Merck & Co. and roles at Johnson & Johnson and Seres Therapeutics. He expressed excitement about Enlivex's Allocetra cell therapy, which aims to restore macrophage function in diseases like sepsis and solid tumors. The company anticipates a cash runway into Q3 2024, positioning it well for future growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.2%
Tags
management
-
Rhea-AI Summary

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced participation in the H.C. Wainwright Global Investment Conference from May 23–26, 2022. The company's presentation will be pre-recorded and accessible throughout the event. Enlivex is developing Allocetra™, a universal cell therapy aimed at reprogramming macrophages to combat diseases such as sepsis and solid tumors. Allocetra™ targets non-homeostatic macrophages that worsen these conditions, potentially offering a new immunotherapeutic approach for serious medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
conferences
-
Rhea-AI Summary

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced participation in the Allogeneic Cell Therapies Summit 2022 and the 20th Biomed Israel Conference. Presentations include topics on their innovative therapy, Allocetra™, targeting solid tumors and cytokine storms linked to sepsis and COVID-19. Key details include a presentation on 'Next Generation Allogeneic Modality for Solid Tumors' on May 10, 2022, and two presentations at the Biomed Israel Conference on May 10 and 12. The focus is on the therapeutic potential of Allocetra™ in treating severe conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.66%
Tags
none
Rhea-AI Summary

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced promising preclinical results for its cell therapy Allocetra™ combined with immune checkpoint inhibitors in treating mesothelioma. A study revealed up to 100% survival in mice receiving the combination treatment versus 0% survival in untreated mice. Allocetra™ alone achieved a 28.5% survival rate. This positions Allocetra™ as a potential innovative therapy for difficult-to-treat solid tumors, prompting plans for clinical trials in 2022 to evaluate its efficacy in patients with advanced-stage cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
none

FAQ

What is the current stock price of Enlivex Therapeutics Ltd. Ordinary Shares (ENLV)?

The current stock price of Enlivex Therapeutics Ltd. Ordinary Shares (ENLV) is $1.24 as of December 20, 2024.

What is the market cap of Enlivex Therapeutics Ltd. Ordinary Shares (ENLV)?

The market cap of Enlivex Therapeutics Ltd. Ordinary Shares (ENLV) is approximately 25.8M.

What is Enlivex Therapeutics Ltd.?

Enlivex Therapeutics Ltd. is an Israel-based clinical-stage immunotherapy company developing allogeneic drugs to rebalance the immune system.

What is Allocetra™?

Allocetra™ is Enlivex's flagship immunotherapy candidate, designed to reprogram macrophages and rebalance the immune system. It is being tested for severe sepsis, COVID-19, GVHD, and more.

What clinical trials are ongoing for Allocetra™?

Allocetra™ is in Phase IIB trials for severe sepsis, Phase II for COVID-19, and Phase IIA for GVHD prevention. Additionally, it's being tested in a Phase I/II trial for knee osteoarthritis.

What recent achievements has Enlivex made?

Enlivex received approval from the Israeli Ministry of Health for a new osteoarthritis trial and announced positive Phase II study results for Allocetra™ in sepsis patients.

What is the significance of Allocetra™ in osteoarthritis treatment?

Allocetra™ is being evaluated for its potential to reprogram macrophages and address the inflammatory causes of osteoarthritis, offering a novel treatment option.

How does Allocetra™ work?

Allocetra™ works by restoring macrophages to their homeostatic state, helping to rebalance the immune system and treat various severe and chronic conditions.

What are the benefits of Enlivex's therapy?

Enlivex's Allocetra™ offers a potential new mechanism of action for treating life-threatening and debilitating conditions by modulating the immune system.

What is the company's financial condition?

Enlivex recently closed a $5 million registered direct offering, indicating strong financial support for its ongoing and future clinical trials.

What are the future plans for Allocetra™?

Enlivex plans to continue expanding its clinical trials for Allocetra™, including potential larger studies for sepsis and ongoing trials for knee osteoarthritis.

Where can I find more information about Enlivex?

For more details, visit Enlivex's official website at http://www.enlivex.com.

Enlivex Therapeutics Ltd. Ordinary Shares

Nasdaq:ENLV

ENLV Rankings

ENLV Stock Data

25.77M
19.34M
5.74%
18.81%
0.46%
Biotechnology
Healthcare
Link
United States of America
Ness Ziona